About AbnomX
AbnomX transforms immune repertoire data into knowledge
AbnomX is a pragmatic immunoinformatics company and trusted advisor to senior researchers of innovative companies and institutions active in the immunology field.
We develop and deploy high-performance software solutions that industrialize antibody discovery and accelerate pre-clinical and clinical immunotherapy development.
Dr. Khalil El Mazouari
Founder, CEO
Khalil El Mazouari is the founder of AbnomX and the architect of both the Antibody-Extractor™ and Abigael Data Platform™. With over 25 years of experience in bioinformatics and immunology, Khalil has led the development of advanced computational systems for antibody engineering and immuno-therapeutic design.
His platforms have supported breakthrough antibody programs, been adopted by leading pharmaceutical companies, and enabled large-scale sequence and workflow management in regulated environments. He has also contributed to the design of sovereign and enterprise-scale platforms for immune repertoire analytics and therapeutic development, providing core scientific and technical leadership from the earliest stages.
Khalil holds a Ph.D. in Molecular Microbiology from the University of Brussels and brings a rare combination of scientific depth, algorithmic rigor, and product vision to the next generation of AI-driven antibody engineering and immune repertoire analytics.
Dr. Mark Vaeck
Early Adviser – Business Strategy
Mark Vaeck has more than 30 years of experience in the biotech and pharma industry. In 2008, he co-founded Complix and was appointed CEO in May 2010. Prior to this, in 2006, Mark co-founded ActoGeniX and served as its CEO until 2010. He was also the founding CEO of Ablynx from 2001 until 2006. As a serial entrepreneur he raised more than €100 million in equity financing for the biotech companies he helped creating. Mark holds a PhD in Immunology from the University of Brussels.
Prof. Hans de Haard
Early Adviser – Scientific Strategy
Hans de Haard has been active in the antibody engineering field since 1989. At the University of Maastricht, he created a large non-immune human Fab library that subsequently became a core asset of Dyax, yielding multiple therapeutic antibodies. Later he served at Ablynx NV as Senior Director Discovery Research. He was responsible for setting up the Nanobody® discovery engine. Currently Hans is the CSO of argenx, a company he co-founded in 2008. He holds a PhD in Molecular Immunology from the University of Maastricht. He is a Professor of Immunology at University of Franche Comté (Besançon, France).
AbnomX is unlike other bioinformatics firms
Focused: Our combined 100+ years of professional experience and 15+ years of AbnomX expertise is focused on solving one key question: how can I leverage software automation in my immune repertoire research to accelerate and optimize my discovery and clinical efforts?
Experienced: Our consultants have on average 10+ years of industry experience and have worked for leading biopharmaceutical companies. They save you precious time and money.
Agile: Our lean organization allows us to move fast and respond quickly.
Pragmatic: We focus on pragmatic, actionable solutions.
Holistic: We offer full-spectrum solutions composed of many complementary modules.
Intelligently separating the signal from the noise
Whether you are a start-up, a midsize company or a large biopharmaceutical company, our team will support you on your journey towards industrialization of antibody discovery and obtaining deep insight in your immune repertoire research, intelligently separating the signal from the noise.
